Recent advances and developments in treatment strategies against pancreatic cancer

Current Clinical Pharmacology

Volumn 4, Issue 2, 2009, Pages 102-112

  Fryer, Rosemary A ^a   Galustian, Christine ^a   Dalgelish, Angus G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Combinations; Gemcitabine; Novel drugs; Pancreatic cancer

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CURCUMIN; DOXORUBICIN; DOXYCYCLINE; FLUOROURACIL; GEMCITABINE; GENISTEIN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOIC ACID;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CARCINOGENICITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; HUMAN; IMMUNOPATHOLOGY; MOLECULAR DYNAMICS; MONOTHERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 68449100485     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488409788185007     Document Type: Review

References (154)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics. Cancer J Clin 2005; 55(4): 259.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. Cancer J Clin 2007; 57(1): 43-66.
3. Sarkar FH, Banerjee S, Li Y. Pancreatic cancer: Pathogenesis, prevention and treatment. Toxicol Appl Pharmacol 2006; 224(3): 326-36.
4. Pezzilli R. Screening tests for pancreatic cancer: searching for the early symptoms or the population at risk. J Pancreas 2004; 5(4): 240-2.
5. Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer 2003; 2: 14.
6. Ujiki MB, Talamonti MS. Surgical management of pancreatic cancer. Semin Radiat Oncol 2005; 15(4): 218-25.
7. Burris HA, III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15(6): 2403-513.
8. Akada M, Crnogorac-Jurcevic T, Lattimore S, et al. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 2005; 11(8): 3094-101.
9. Macdonald JS, McCoy S, Whitehead RP, et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Investig New Drugs 2005; 23(5): 485-7.
10. Cohen SJ, Meropol NJ. Drug development in pancreatic cancer: finally, biology begets therapy. Int J Gastrointest Cancer 2002; 32(2-3): 91-106.
11. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87(2): 161-7.
12. Banerjee S, Zhang Y, Ali S, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005; 65(19): 9064-72.
13. Buchler P, Gukovskaya AS, Mouria M, et al. Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genistein, a naturally occurring isoflavonoid. Pancreas 2003; 26(3): 264-73.
14. Lev-Ari S, Vexler A, Starr A, et al. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Investig 2007; 25(6): 411-8.
15. Andea AA, Basturk O, Adsay NV. Pancreatic intra-epithelial neoplasia: current clinicopathological and molecular considerations. Curr Diagn Pathol 2005; 11: 80-94.
16. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; (2): 211-26.
17. Kleeff J, Beckhove P, Esposito I, et al. Pancreatic cancer microenvironment. Int J Cancer 2007; 121(4): 699-705.
18. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9(6): 667-76.
19. Mimeault M, Brand RE, Sasson AA, Batra SK. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 2005; 31(4): 301-16.
20. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 2003; 89(2): 391-7.
21. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN. Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 2005; 24(44): 6719-28.
22. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3- kinase/ Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004; 23(53): 8571-80.
23. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002; 1(12): 989-97.
24. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993; 105(6): 1846-56.
25. Massague J. TGFbeta in Cancer. Cell 2008; 134(2): 215-30.
26. Pardali K, Kurisaki A, Moren A, ten DP, Kardassis D, Moustakas A. Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem 2000; 275(38): 29244-56.
27. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6(8): 2969-72.
28. Liu F. SMAD4/DPC4 and pancreatic cancer survival. Commentary re: M. Tascilar et al., The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001; 7(12): 3853-6.
29. Chow JY, Quach KT, Cabrera BL, Cabral JA, Beck SE, Carethers JM. RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis 2007; 28(11): 2321-7.
30. Ebert MP, Fei G, Schandl L, et al. Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer 2002; 86(2): 257-62.
31. Reichert M, Saur D, Hamacher R, Schmid RM, Schneider G. Phosphoinositide- 3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res 2007; 67(9): 4149-56.
32. Takeda A, Osaki M, Adachi K, Honjo S, Ito H. Role of the phosphatidylinositol 3′-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 2004; 28(3): 353-8.
33. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2(12): 897-909.
34. Doucas H, Garcea G, Neal CP, Manson MM, Berry DP. Chemoprevention of Pancreatic cancer: a review of the molecular pathways involved, and evidence for the Potential for Chemoprevention. Pancreatology 2006; 6: 429-39.
35. Taghavi MH, Davoodi J. Restoration of p53 functions suppresses tumor growth of pancreatic cells with different p53 status. Cancer Biother Radiopharm 2007; 22(3): 322-32.
36. Hosotani R, Miyamoto Y, Fujimoto K, et al. Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin Cancer Res 2002; 8(4): 1271-6.
37. Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008; 7: 64-74.
38. Mortenson MM, Galante JG, Gilad O, et al. BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. J Cell Biochem 2007; 102(5): 1171-9.
39. Greten FR, Weber CK, Greten TF, et al. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 2002; 123(6): 2052-63.
40. Holcomb B, Yip-Schneider M, Schmidt CM. The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 2008; 36(3): 225-35.
41. Cheng Q, Lee HH, Li Y, Parks TP, Cheng G. Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene 2000; (42): 4936-40.
42. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 2003; 105(6): 735-46.
43. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5(1): 119-27.
44. Lopes RB, Gangeswaran R, McNeish IA, Wang Y, Lemoine NR. Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer 2007; 120(11): 2344-52.
45. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002; 86(6): 886-92.
46. Qiao JG, Zhang YQ, Yin YC, Tan Z. Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2. World J Gastroenterol 2004; 10(18): 2759-61.
47. Esposito I, Kleeff J, Abiatari I, et al. Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J Clin Pathol 2007; 60(8): 885-95.
48. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001; 92(2): 271-8.
49. Lee MA, Park GS, Lee HJ, et al. Survivin expression and its clinical significance in pancreatic cancer. BMC Cancer 2005; 5: 127.
50. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67(19): 9518-27.
51. Liyanage UK, Goedegebuure PS, Moore TT, et al. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother 2006; 29(4): 416-24.
52. Yanagimoto H, Takai S, Satoi S, et al. Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol 2005; 114(1): 52-60.
53. Sakorafas GH, Tsiotou AG, Tsiotos GG. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 2000; 26(1): 29-52.
54. Schneider C, Schmidt T, Ziske C, et al. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 2004; 53(3): 355-61.
55. Mancuso A, Calabro F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 2006; 58(3): 231-41.
56. Shore S, Raraty MGT, Ghaneh P, Neoptolemos JP. Review article: chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 2003; 18: 1049-69.
57. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3(5): 330-8.
58. Balart J, Capella G, de l, I, et al. Treatment with 5-fluorouracil enhances radiosensitivity of the human pancreatic cancer cell line MiaPaCa-2. Pancreatology 2002; 2(1): 40-5.
59. Eisold S, Linnebacher M, Ryschich E, et al. The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J Gastroenterol 2004; 10(24): 3583-9.
60. Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62(4): 354-62.
61. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular Pharmacology of Gemcitabine. Ann Oncol 2006; 17 (suppl 5): v7-v12.
62. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23(5 Suppl 10): 3-15.
63. Chandler NM, Canete JJ, Callery MP. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. J Gastrointest Surg 2004; 8(8): 1072-8.
64. Nabhan C, Gajria D, Krett NL, Gandhi V, Ghias K, Rosen ST. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther 2002; 1(13): 1221-7.
65. Habiro A, Tanno S, Koizumi K, et al. Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun 2004; 316(1): 71-7.
66. Koizumi K, Tanno S, Nakano Y, et al. Activation of p38 mitogen-activated protein kinase is necessary for gemcitabine-induced cytotoxicity in human pancreatic cancer cells. Anticancer Res 2005; 25(5): 3347-53.
67. Zhao Y, Shen S, Guo J, et al. Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res 2006; 136(2): 325-35.
68. Pham NA, Tsao MS, Cao P, Hedley DW. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models. Pancreas 2007; 35(3): e16-26.
69. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000; 60(19): 5451-5.
70. Tsuruta F, Masuyama N, Gotoh Y. The phosphatidylinositol 3- kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J Biol Chem 2002; 277(16): 14040-7.
71. Blanco-Aparicio C, Pequeno B, Moneo V, et al. Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low passage tumor cell lines correlating with Bax translocation to the mitochondria. Anti-Cancer Drugs 2005; 16(9): 977-87.
72. Xu Z, Friess H, Solioz M, et al. Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer 2001; 94(2): 268-74.
73. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 1999; 6(3): 279-85.
74. Schniewind B, Christgen M, Kurdow R, et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria- mediated apoptosis. Int J Cancer 2004; 109(2): 182-8.
75. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-kappaB and Akt/ PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22(21): 3243-51.
76. Shrikhande SV, Kleeff J, Kayed H, et al. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer Res 2006; 26(5A): 3265-73.
77. Li Y, Jian Z, Xia K, et al. XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas 2006; 32(3): 288-96.
78. Karikari CA, Roy I, Tryggestad E, et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2007; 6(3): 957-66.
79. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 2002; 97(4): 439-45.
80. Cascallo M, Calbo J, Gelpi JL, Mazo A. Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. Cancer Gene Ther 2000; 7(4): 545-56.
81. Calbo J, Marotta M, Cascallo M, et al. Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther 2001; 8(10): 740-50.
82. Ohhashi S, Ohuchida K, Mizumoto K, et al. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res 2008; 28(4B): 2205-12.
83. Kroep JR, Loves WJ, van der Wilt CL, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002; 1(6): 371-6.
84. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100(12): 2491-9.
85. Ko AH, Dito E, Schillinger E, et al. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 2008; 26(5): 463-71.
86. Fife RS, Rougraff BT, Proctor C, Sledge GW, Jr. Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med 1997; 130(5): 530-4.
87. Richardson M, Wong D, Lacroix S, Stanisz J, Singh G. Inhibition by doxycycline of angiogenesis in the chicken chorioallantoic membrane (CAM). Cancer Chemother Pharmacol 2005; 56(1): 1-9.
88. Mouratidis PX, Colston KW, Dalgleish AG. Doxycycline induces caspase-dependent apoptosis in human pancreatic cancer cells. Int J Cancer 2007; 120(4): 743-52.
89. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56(2): 185-229.
90. Kingma PS, Osheroff N. Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage. J Biol Chem 1997; 272(11): 7488-93.
91. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002; 303(1): 124-31.
92. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57(7): 727-41.
93. Shapiro GI, Edwards CD, Ewen ME, Rollins BJ. p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 1998; 18(1): 378-87.
94. Ling YH, el-Naggar AK, Priebe W, Perez-Soler R. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 1996; 49(5): 832-41.
95. Lee JU, Hosotani R, Wada M, et al. Mechanism of apoptosis induced by cisplatin and VP-16 in PANC-1 cells. Anticancer Res 1997; 17(5A): 3445-50.
96. Arlt A, Vorndamm J, Breitenbroich M, et al. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001; (7): 859-68.
97. Lu Y, Yu Q, Liu JH, et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/ AKT cascades. J Biol Chem 2003; 278(41): 40057-66.
98. Goodell JR, Ougolkov AV, Hiasa H, et al. Acridine-based agents with topoisomerase II activity inhibit pancreatic cancer cell proliferation and induce apoptosis. J Med Chem 2008; 51(2): 179-82.
99. Lin JK. Molecular targets of curcumin. Adv Exper Med Biol 2007; 595: 227-43.
100. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (Diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkBa kinase and Akt activation. Mol Pharmacol 2006; 69: 195-206.
101. Woo JH, Kim YH, Choi YJ, et al. Molecular mechanisms of curcumin- induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003; 24(7): 1199-208.
102. Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclindependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 2007; 73(7): 1024-32.
103. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004; 101(10): 2351-62.
104. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14(14): 4491-9.
105. Jagetia GC, Aggarwal BB. "Spicing up" of the immune system by curcumin. J Clin Immunol 2007; 27(1): 19-35.
106. Chakraborty S, Ghosh U, Bhattacharyya NP, Bhattacharyya RK, oy M. Inhibition of telomerase activity and induction of apoptosis by curcumin in K-562 cells. Mutat Res 2006; 596: 81-90.
107. Thasni KA, Rojini G, Rakesh SN, et al. Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status. Eur J Pharmacol 2008; 588(2-3): 158-64.
108. Gong L, Li Y, Nedeljkovic-Kurepa A, Sarkar FH. Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 2003; 22(30): 4702-9.
109. Matsumura K, Tanaka T, Kawashima H, Nakatani T. Involvement of the estrogen receptor beta in genistein-induced expression of p21(waf1/cip1) in PC-3 prostate cancer cells. Anticancer Res 2008; 28(2A): 709-14.
110. Farivar RS, Gardner-Thorpe J, Ito H, et al. The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines. J Surg Res 2003; 115(2): 219-25.
111. Ischenko I, Guba M, Yezhelyev M, et al. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis 2007; 10(3): 167-82.
112. Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 2003; 134(2): 221-6.
113. Summy JM, Trevino JG, Baker CH, Gallick GE. c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 2005; 31(3): 263-74.
114. Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH. Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer 2006; 118(8): 1930-6.
115. Buchler P, Reber HA, Buchler MW, Friess H, Lavey RS, Hines OJ. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer 2004; 100(1): 201-10.
116. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16(9): 4604-13.
117. van UP, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 2008; 412(3): 477-84.
118. Majid S, Kikuno N, Nelles J, et al. Genistein induces the p21WAF1/ CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res 2008; 68(8): 2736-44.
119. Shen JC, Klein RD, Wei Q, et al. Low-dose genistein induces cyclin- dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 2000; 29(2): 92-102.
120. Davis JN, Singh B, Bhuiyan M, Sarkar FH. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 1998; 32(3): 123-31.
121. Schmidt F, Knobbe CB, Frank B, Wolburg H, Weller M. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines. Oncol Rep 2008; (4): 1061-6.
122. Li M, Zhang Z, Hill DL, Chen X, Wang H, Zhang R. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res 2005; 65(18): 8200-8.
123. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1(3): 181-93.
124. Guo J, Xiao B, Lou Y, et al. Antitumor effects of all-trans-retinoic acid on cultured human pancreatic cancer cells. J Gastroenterol Hepatol 2006; 21(2): 443-8.
125. Zhu WY, Jones CS, Kiss A, Matsukuma K, Amin S, De Luca LM. Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells. Exp Cell Res 1997; 234(2): 293-9.
126. Balasubramanian S, Chandraratna RA, Eckert RL. A novel retinoid- related molecule inhibits pancreatic cancer cell proliferation by a retinoid receptor independent mechanism via suppression of cell cycle regulatory protein function and induction of caspase-associated apoptosis. Oncogene 2005; 24(26): 4257-70.
127. El-Metwally TH, Hussein MR, Pour PM, Kuszynski CA, Adrian TE. High concentrations of retinoids induce differentiation and late apoptosis in pancreatic cancer cells in vitro. Cancer Biol Ther 2005; 4(5): 602-11.
128. Leelawat K, Ohuchida K, Mizumoto K, Mahidol C, Tanaka M. Alltrans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett 2005; 224(2): 303-10.
129. Pettersson F, Dalgleish AG, Bissonnette RP, Colston KW. Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br J Cancer 2002; 87(5): 555-61.
130. Vertuani S, Dubrovska E, Levitsky V, Jager MJ, Kiessling R, Levitskaya J. Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells. Cancer Immunol Immunother 2007; 56: 193-204.
131. Darmanin S, Chen J, Zhao S, et al. All-trans retinoic acid enhances murine dendritic cell migration to draining lymph nodes via the balance of matrix metalloproteinases and their inhibitors. J Immunol 2007; 179(7): 4616-25.
132. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59(5): 987-90.
133. Okami J, Nakamori S, Hiraoka N, et al. Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor. Clin Exp Metastasis 2003; (7): 577-84.
134. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999; 59(17): 4356-62.
135. Covey TM, Edes K, Fitzpatrick FA. Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene 2007; 26(39): 5784-92.
136. Hughes-Fulford M, Li CF, Boonyaratanakornkit J, Sayyah S. Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer. Cancer Res 2006; 66(3): 1427-33.
137. Kim N, Kim CH, Ahn DW, et al. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. J Gastroenterol Hepatol 2008; Epub ahead of print.
138. Liu B, Shi ZL, Feng J, Tao HM. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int 2008; 32(5): 494-501.
139. El-Rayes BF, Ali S, Sarkar FH, Philip PA. Cyclooxygenase-2- dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther 2004; 3(11): 1421-6.
140. Poligone B, Baldwin AS. Positive and negative regulation of NFkappaB by COX-2: roles of different prostaglandins. J Biol Chem 2001; 276(42): 38658-64.
141. Sclabas GM, Uwagawa T, Schmidt C, et al. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 2005; 103(12): 2485-90.
142. Eibl G, Reber HA, Wente MN, Hines OJ. The selective cyclooxygenase- 2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 2003; 26(1): 33-41.
143. Tatsuguchi A, Matsui K, Shinji Y, et al. Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol 35(4):488-95, 2004.
144. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004; 64(6): 2030-8.
145. Abdelrahim M, Smith R, III, Burghardt R, Safe S. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 2004; 64(18): 6740-9.
146. Higgins KJ, Abdelrahim M, Liu S, Yoon K, Safe S. Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun 2006; 345(1): 292-301.
147. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007; 67(8): 3853-61.
148. Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, Marshall MS. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001; 298(3): 976-85.
149. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NFkappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 2001; 12(1): 73-90.
150. Ferrari V, Valcamonico F, Amoroso V, et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 2006; 57(2): 185-90.
151. Dragovich T, Burris H, III, Loehrer P, et al. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol 2008; 31(2): 157-62.
152. Nakagawa T, Shimizu M, Shirakami Y, et al. Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. Cancer Lett 2008; [Epub ahead of print].
153. Pettersson F, Colston KW, Dalgleish AG. Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas 2001; 23(3): 273-9.
154. Michael A, Hill M, Maraveyas A, Dalgleish A, Lofts F. 13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer - report of a pilot phase II study. Clin Oncol (Royal College of Radiologists) 2007; (2): 150-3.